Ambev S.A. filings document the reporting cycle of a Brazilian foreign private issuer with NYSE ADRs and B3-listed common shares. Form 20-F reports cover audited financial statements and annual business disclosure, while Form 6-K submissions furnish interim consolidated financial statements, quarterly operating results and current reports under Exchange Act rules for foreign issuers.
The filing record also covers beverage segment performance in Brazil Beer, Brazil NAB, Latin America South, Central America and the Caribbean, and Canada; capital allocation through interest on capital; treasury share activity; management and related-person securities transactions under Brazilian CVM rules; shareholder-meeting voting maps; board resolutions; committee matters; compensation; and other governance disclosures.
AMBEV S.A. officer Eduardo Braga Cavalcanti de Lacerda filed an initial ownership report listing his equity interests in the company. The filing shows multiple grants of restricted shares, each representing a contingent right to receive one common share, generally at no exercise price and subject to withholding taxes.
These restricted shares vest on various dates, including December 1, 2026, March 1, 2027, December 2, 2027, February 28, 2028, December 1, 2028, and December 18, 2028. He also holds several stock option awards over common shares with exercise prices between $3.22 and $3.91 per share, expiring between 2026 and 2029, as well as directly held common shares. The report records existing holdings rather than new market transactions.
AMBEV S.A. officer Duarte Valdecir filed an initial ownership report showing direct holdings of 705,363 common shares. The filing also lists multiple grants of restricted shares, each representing a right to receive one common share minus withholding taxes, vesting on dates from December 1, 2026 through December 1, 2028.
In addition, he holds several stock option awards over common shares with exercise prices such as 3.26, 3.91, 3.22 and 3.43 per share, expiring between December 2, 2026 and December 3, 2029. The entry is a Form 3, so it records existing positions rather than new market purchases or sales.
AMBEV S.A. director Carlos De Marchi Victorio filed an initial Form 3 reporting his equity interests in the company. He reports direct ownership of 1,477,693 common shares and indirect ownership of 25,653,369 common shares through DM Investimentos S.A., where he is the financial beneficial owner.
He also reports multiple grants of restricted shares that each represent a right to receive one common share minus withholding taxes, with vesting dates running from December 1, 2026 through December 1, 2030. In addition, he holds several stock option awards over hundreds of thousands of common shares with exercise prices between 3.22 and 3.91 and expirations from 2026 to 2029.
AMBEV S.A. director Lia Machado de Matos filed an initial ownership report showing several awards of restricted shares tied to Ambev common stock. The positions include blocks of restricted shares corresponding to 26,312 and 28,641 underlying common shares held directly, among other tranches.
Footnotes explain that each restricted share represents a contingent right to receive one common share minus withholding taxes, with vesting dates on December 1, 2026, December 1, 2027, December 1, 2028, December 2, 2029, and December 1, 2030. The filing reports these holdings and does not disclose any open-market purchases or sales.
AMBEV S.A. director Fernanda Gemael Hoefel reported an initial holding of 33,289 restricted shares. These restricted shares vest on December 1, 2030. Each restricted share represents a contingent right to receive one common share, reduced by any shares withheld to cover applicable taxes.
AMBEV S.A. Chief Executive Officer Carlos Eduardo Klutzenschell Lisboa filed an initial ownership report showing his equity position in the company. He directly holds 1,796,070 common shares.
He also holds 1,034,028 restricted shares, each representing a contingent right to receive one common share, minus withholding taxes. These restricted shares vest on December 12, 2028, meaning they convert into common shares only if vesting conditions are met by that date.
AMBEV S.A. director de Almeida David Henrique Galatro has filed an initial ownership report, showing that he holds 475 common shares of the company. This Form 3 filing simply establishes his current direct stake and does not report any recent share purchases or sales.
AMBEV S.A. executive Parolari Guilherme Fleury de Figueiredo Ferraz filed an initial ownership report showing direct holdings in common and equity awards. He holds 19,893 common shares and 168,353 restricted shares that vest on December 1, 2028, each representing a right to receive one common share minus withholding taxes.
He also holds stock options over 67,658 common shares at an exercise price of 3.2600 expiring on December 2, 2026, 233,781 shares at 3.1100 expiring on December 23, 2026, 80,393 shares at 3.9100 expiring on December 2, 2027, and 103,453 shares at 3.2200 expiring on December 4, 2028. The filing reflects existing holdings rather than new market purchases or sales.
AMBEV S.A. director Luciana Pires Dias filed an initial ownership report showing awards of restricted shares tied to common shares and a small direct common share position. She holds restricted shares representing 38,689 common shares vesting on December 1, 2028, 39,505 vesting on December 2, 2029, and 33,289 vesting on December 1, 2030. She also directly owns 3,000 common shares. Each restricted share gives a contingent right to receive one common share, reduced by withholding taxes.
AMBEV S.A. director Milton Seligman filed an initial Form 3 reporting his equity holdings in the company. He directly owns 545,090 common shares and holds several grants of restricted shares that each represent a contingent right to receive one common share, minus withholding taxes, upon vesting.
The filing also lists stock options giving him the right to buy 52,949 common shares at an exercise price of 3.2200 per share exercisable until December 4, 2028, and 72,370 common shares at 3.4300 per share exercisable until December 3, 2029. Restricted share awards vest on dates ranging from December 1, 2026 through December 1, 2030.